Precision BioSciences, Inc. (NASDAQ:DTIL) Insider Sells $49,274.73 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) insider J. Jefferson Smith sold 10,287 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total value of $49,274.73. Following the completion of the sale, the insider now owns 87,440 shares of the company’s stock, valued at approximately $418,837.60. This trade represents a 10.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Precision BioSciences Stock Up 1.6 %

DTIL opened at $5.08 on Friday. The business has a 50 day moving average of $5.46 and a 200-day moving average of $7.96. The stock has a market capitalization of $38.96 million, a price-to-earnings ratio of 84.68 and a beta of 1.51. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences, Inc. has a 1-year low of $3.61 and a 1-year high of $19.43.

Institutional Trading of Precision BioSciences

A hedge fund recently raised its stake in Precision BioSciences stock. Janus Henderson Group PLC increased its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 702,069 shares of the company’s stock after buying an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on DTIL shares. BMO Capital Markets upgraded shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a research note on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Precision BioSciences in a report on Friday, January 10th.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.